Canadian firm Valeo Pharma revealed the extent of coverage for its Lovenox biosimilars, months after launching the low molecular weight heparin in-licensed from Shenzhen Techdow Pharmaceutical.

A favorable court ruling has allowed Sandoz Canada to launch the first generic version of Roche’s Esbriet to treat idiopathic pulmonary fibrosis.

Sandoz Canada has taken another “important step as we pursue our ambition to become the leading biosimilars and generics company” with the launch of biosimilar enoxaparin.

Sandoz has confirmed the launch of its Hyrimoz biosimilar rival to Humira in Canada, with other biosimilars firms having also set their sights on a mid-February launch.